Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1535
interventional 1341
Observational 183
Registry 11

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 564
Biological 255
Biological|Drug 111
Biological|Other 34
Procedure 34
Drug|Other 32
Other 31
Drug|placebo 29
Biological|Drug|Other 28
Behavioral 22
Drug|Procedure 21
Drug|Radiation 16
Biological|Drug|Procedure 14
Biological|Procedure 13
Device 13
Radiation 13
Drug|Other|Procedure 10
Behavioral|Other 6
Biological|Radiation 6
Biological|Device 5
Biological|Drug|Radiation 5
Biological|placebo 5
Device|Drug 5
Biological|Drug|Genetic|Other|Procedure 4
Biological|Drug|placebo 4
Biological|Other|Procedure 4
Combination Product 4
Genetic 4
Biological|Other|Radiation 3
Diagnostic Test 3
Diagnostic Test|Drug 3
Biological|Drug|Other|Procedure 2
Biological|Drug|Procedure|Radiation 2
Biological|Genetic 2
Device|Drug|Procedure 2
Device|Procedure 2
Drug|Genetic 2
Drug|Other|placebo 2
Drug|Procedure|Radiation 2
Other|Radiation 2
Procedure|Radiation 2
Behavioral|Drug 1
Biological|Device|Other 1
Biological|Dietary Supplement 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Radiation 1
Biological|Other|placebo 1
Dietary Supplement 1
Dietary Supplement|Drug 1
Dietary Supplement|Other 1
Dietary Supplement|placebo 1
Drug|Genetic|Other 1
Drug|Genetic|Procedure 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1
Genetic|Other 1
Genetic|Other|Radiation 1
Genetic|Procedure 1
Genetic|Radiation 1
Other|Procedure 1
Other|Procedure|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 776
NA 42
France 40
Germany 29
China 28
Australia 19
Canada 19
Switzerland 18
Netherlands 17
United Kingdom 17
United States|Australia 17
United States|Canada 15
Denmark 14
Italy 14
Belgium 12
Sweden 10
Israel 9
Japan 8
Norway 8
Korea, Republic of 6
United States|United Kingdom 6
Spain 5
Russian Federation 4
Austria|Germany 3
United States|Israel 3
United States|Puerto Rico 3
Austria 2
United States|Australia|Canada 2
United States|Australia|Germany|United Kingdom 2
United States|Australia|Switzerland 2
United States|Belgium|Canada|Spain 2
United States|France 2
United States|Netherlands|Spain 2
United States|Norway 2
United States|Norway|Sweden 2
United States|Sweden 2
Albania|Argentina|Australia|Austria|Belgium|Bosnia and Herzegovina|Brazil|Bulgaria|Canada|Colombia|Croatia|Czechia|Denmark|Ecuador|Estonia|Finland|Germany|Greece|Hungary|India|Ireland|Israel|Italy|Korea, Republic of|Latvia|Lithuania|Macedonia, The Former Yugoslav Republic of|Mexico|Netherlands|Norway|Peru|Poland|Portugal|Romania|Russian Federation|Serbia|Slovakia|Slovenia|South Africa|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Argentina 1
Argentina|Australia|Brazil|Canada|Czechia|Finland|France|Greece|Hungary|Israel|Italy|Japan|Latvia|Lithuania|Norway|Poland|Portugal|Russian Federation|Slovakia|Slovenia|Sweden|Turkey|United Kingdom 1
Argentina|Australia|Canada|Chile|Denmark|Finland|France|Germany|Greece|Israel|Italy|Mexico|Norway|Poland|Spain|Sweden 1
Australia|Austria|Belgium|Finland|France|Germany|Ireland|Italy|Norway|Sweden|Switzerland|United Kingdom 1
Australia|Austria|France|Germany|Italy|Netherlands|Switzerland|United Kingdom 1
Australia|Austria|Netherlands|Sweden 1
Australia|Brazil|Italy|Netherlands|Slovenia|United Kingdom 1
Australia|Brazil|Netherlands|New Zealand 1
Australia|Canada 1
Australia|Estonia|Germany|Latvia|Lithuania|Netherlands|South Africa|Ukraine|United Kingdom 1
Australia|France|Italy|Spain 1
Australia|Germany|Greece|Hungary|Netherlands|New Zealand|Portugal|Serbia|Spain 1
Australia|India|New Zealand 1
Australia|New Zealand|United Kingdom 1
Australia|Norway|United Kingdom 1
Australia|South Africa|Spain|Sweden 1
Austria|Belgium|Czechia|Finland|Germany|Greece|Hungary|Ireland|Italy|Luxembourg|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Portugal|Spain|Switzerland|United Kingdom 1
Austria|Belgium|Denmark|France|Germany|Netherlands|Norway|Switzerland|United Kingdom 1
Austria|Belgium|France|Germany|Italy|Norway|Portugal|Switzerland|United Kingdom 1
Austria|France|Germany|Greece|Italy|Poland|Spain|Sweden|Switzerland|United Kingdom 1
Austria|France|Germany|Switzerland 1
Belgium|Finland|Germany|Netherlands|Spain 1
Belgium|France 1
Belgium|France|Germany|Italy|Netherlands|Poland|Spain|United Kingdom 1
Belgium|Hungary 1
Belgium|Poland 1
Belgium|Spain 1
Brazil 1
Brazil|France|Germany|Hungary|Italy|Latvia|Spain|Switzerland 1
Bulgaria|Canada|India|Russian Federation|Slovakia|South Africa|Spain 1
China|Hong Kong|Korea, Republic of|Taiwan|Thailand 1
China|Korea, Republic of 1
Cuba 1
Denmark|France 1
Denmark|Netherlands 1
Finland 1
France|Germany 1
France|Germany|Greece|Serbia 1
France|Germany|Hungary|Italy|Poland|Portugal|Spain|Switzerland 1
France|Germany|Spain 1
France|Germany|Switzerland 1
France|Switzerland 1
France|United Kingdom 1
France|United States|Australia|Canada|Czechia|Germany|Italy|Netherlands|Spain|Sweden|United Kingdom 1
France|United States|Belgium|Brazil|Canada|Germany|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|Switzerland|Turkey 1
France|United States|Germany 1
Germany|Austria|Belgium|France|Italy|Netherlands|Portugal|Switzerland|United Kingdom 1
Germany|Greece|Hungary|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Chile|Czechia|Denmark|France|Israel|Italy|Japan|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
Germany|Italy 1
Germany|Switzerland 1
Germany|United States|Australia|Austria|Belgium|Brazil|Canada|Czechia|France|Greece|Israel|Italy|New Zealand|Poland|Romania|Russian Federation|Spain|Switzerland|United Kingdom 1
Greece|Italy|Poland|Spain|United States|Australia|France|Germany 1
Hong Kong 1
Hungary 1
Hungary|Italy|United States|Australia|Russian Federation|Sweden|Ukraine|United Kingdom|Poland 1
Hungary|United States|Austria|France|Italy|Poland|Romania|Spain 1
India 1
Ireland 1
Ireland|Italy|Poland|United States|France|Germany|Russian Federation|Spain 1
Israel|Korea, Republic of|Belarus|Russian Federation|South Africa 1
Italy|Poland|Czechia|France|Germany|Russian Federation 1
Italy|United States|Australia|Belgium|Canada|Chile|Denmark|France|Germany|Ireland|Israel|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Russian Federation|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
Italy|United States|Australia|Canada|France|Germany|Israel|Netherlands|New Zealand|Sweden|Switzerland|United Kingdom 1
Korea, Republic of|Netherlands|Serbia|United Kingdom 1
Netherlands|Sweden 1
Netherlands|United Kingdom 1
New Zealand|Norway|Poland|Spain|United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Ireland|Israel|Italy|Netherlands|Sweden|Switzerland|United Kingdom 1
New Zealand|United Kingdom 1
Poland|Spain 1
Singapore 1
South Africa 1
South Africa|United States|Australia|Bosnia and Herzegovina|Brazil|Korea, Republic of|Poland|Spain|Ukraine 1
Spain|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|France|Germany|Greece|Israel|Italy|Japan|Netherlands|New Zealand|Norway|Poland|Russian Federation|Sweden|Switzerland|Taiwan|United Kingdom 1
Spain|United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Poland|Portugal|Russian Federation|United Kingdom 1
Sweden|Switzerland|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Korea, Republic of|Netherlands|New Zealand|Norway|Poland|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom 1
Sweden|Ukraine|United States|Austria|Finland|Italy|Norway|Poland|Russian Federation|Spain 1
Sweden|United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Italy|Netherlands|Norway|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
Taiwan 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Colombia|Denmark|Finland|France|Germany|Greece|Israel|Italy|Mexico|New Zealand|Norway|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czech Republic|France|Germany|Hungary|Ireland|Israel|Italy|Netherlands|Norway|Poland|Portugal|Russian Federation|South Africa|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Finland|France|Germany|Greece|Ireland|Israel|Italy|Netherlands|New Zealand|Poland|Portugal|Romania|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Croatia|Czechia|Estonia|France|Germany|Ireland|Israel|Italy|Mexico|Netherlands|New Zealand|Norway|Poland|Portugal|Russian Federation|Serbia|South Africa|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Portugal|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|Czechia|Denmark|France|Germany|Hungary|Israel|Italy|Mexico|Netherlands|Norway|Poland|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|Czechia|Finland|France|Greece|Hungary|Ireland|Italy|Japan|Korea, Republic of|Netherlands|Norway|Poland|Romania|South Africa|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Greece|Italy|New Zealand|Norway|Poland|Russian Federation|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Canada|France|Germany|Greece|Israel|Italy|Mexico|Netherlands|Poland|Russian Federation|Slovakia|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|Denmark|France|Switzerland|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Germany|Italy|Netherlands|Singapore|Spain|Sweden|Switzerland 1
United States|Argentina|Australia|Belgium|Italy|New Zealand 1
United States|Argentina|Australia|Brazil|Canada|Chile|France|Ireland|Italy|Mexico|New Zealand|Poland|Romania|Spain 1
United States|Argentina|Australia|Brazil|Canada|Colombia|Czechia|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Portugal|Russian Federation|Singapore|Slovakia|South Africa|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
United States|Argentina|Australia|Canada|France|Germany|Greece|Italy|Netherlands|Russian Federation|Spain|Sweden|Ukraine|United Kingdom 1
United States|Argentina|Australia|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Canada|Czech Republic|Denmark|France|Germany|Israel|Italy|Norway|Poland|Russian Federation|South Africa|Spain|Ukraine 1
United States|Argentina|Belgium|Brazil|Bulgaria|Canada|China|France|Germany|Greece|Hungary|India|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Netherlands|Peru|Poland|Portugal|Romania|Russian Federation|Spain|Switzerland|Taiwan|Thailand|Turkey 1
United States|Argentina|France|Hungary|Spain|Thailand 1
United States|Australia|Austria|Belgium|Canada|Czechia|Denmark|Finland|France|Germany|Greece|Italy|Netherlands|Norway|Poland|Romania|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|Finland|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Russian Federation|South Africa|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Hungary|Israel|Italy|Netherlands|New Zealand|Norway|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Israel|Italy|Spain 1
United States|Australia|Austria|Canada|Czech Republic|France|Germany|Italy|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Poland|South Africa|Spain|Switzerland|United Kingdom 1
United States|Australia|Belgium|Brazil|Canada|Czech Republic|France|Germany|Hungary|South Africa 1
United States|Australia|Belgium|Brazil|France|Germany|Greece|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Italy|Netherlands|Poland|Russian Federation|Spain|Switzerland|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|France|Russian Federation|Spain 1
United States|Australia|Belgium|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Belgium|France|Germany|Israel|Italy|Netherlands|New Zealand|South Africa|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|France|Germany|Italy|Korea, Republic of|Poland|Spain|Sweden 1
United States|Australia|Belgium|Germany|United Kingdom 1
United States|Australia|Brazil|Canada|Chile|France|Germany|Israel|Italy|Korea, Republic of|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Brazil|France|Germany|Israel|Italy|Korea, Republic of|New Zealand|Sweden|United Kingdom 1
United States|Australia|Brazil|France|Greece|Poland|Russian Federation|Spain|Switzerland 1
United States|Australia|Canada|Czechia|France|Germany|Greece|Ireland|Italy|Japan|Netherlands|New Zealand|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany|Israel|Italy|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Canada|Finland|Germany|Israel|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Canada|France|Germany|Hungary|Ireland|Italy|Netherlands|Poland|Russian Federation|Spain 1
United States|Australia|Canada|France|Germany|Israel|Italy|Netherlands|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy 1
United States|Australia|Canada|France|Germany|Italy|Netherlands|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Spain 1
United States|Australia|Canada|France|Germany|Netherlands|United Kingdom 1
United States|Australia|Canada|Germany|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
United States|Australia|Canada|South Africa 1
United States|Australia|Canada|Spain|Sweden 1
United States|Australia|Canada|Sweden|United Kingdom 1
United States|Australia|France|Germany|Italy 1
United States|Australia|France|Italy|Japan 1
United States|Australia|France|Japan|Norway|Spain|Switzerland 1
United States|Australia|France|Netherlands|Norway|Spain 1
United States|Australia|Germany|Italy|Netherlands 1
United States|Australia|Israel|Korea, Republic of|Norway 1
United States|Australia|Israel|Switzerland 1
United States|Australia|Korea, Republic of|Netherlands|Spain 1
United States|Australia|Peru|Puerto Rico 1
United States|Australia|Sweden|United Kingdom 1
United States|Australia|United Kingdom 1
United States|Austria|Belgium|Brazil|Canada|Denmark|France|Germany|Israel|Italy|Netherlands|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|France|Germany|Greece|Hungary|Italy|Netherlands|Poland|Russian Federation|Spain|United Kingdom 1
United States|Austria|Belgium|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Belgium|Canada|Czech Republic|Finland|France|Germany|Israel|Netherlands|Spain|United Kingdom 1
United States|Belgium|Canada|France|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Finland|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Spain|Switzerland 1
United States|Brazil|Argentina|Belgium|Canada|Chile|France|Germany|Hungary|Netherlands|South Africa|Switzerland|United Kingdom 1
United States|Brazil|Canada|Cyprus|Korea, Republic of 1
United States|Brazil|Croatia|Egypt|South Africa 1
United States|Brazil|Czech Republic|France|Germany|Hungary|Netherlands|Norway|Spain|Sweden|Switzerland|United Kingdom 1
United States|Bulgaria|Korea, Republic of|Malaysia|Poland|Russian Federation|Ukraine 1
United States|Canada|Denmark|France|Germany|Italy 1
United States|Canada|Denmark|Germany|Italy|United Kingdom 1
United States|Canada|France|Italy 1
United States|Canada|France|Italy|Spain|Switzerland|United Kingdom 1
United States|Canada|Germany|Spain|United Kingdom 1
United States|Canada|Ireland 1
United States|Canada|Israel|Italy|Peru|United Kingdom 1
United States|Canada|Japan|Netherlands|Singapore|Spain 1
United States|Canada|South Africa|United Kingdom 1
United States|Canada|Spain 1
United States|China 1
United States|Czechia|Italy|New Zealand 1
United States|Denmark|Israel|Italy|Norway|Peru|Sweden 1
United States|France|Germany|Hungary|Italy|Spain|Switzerland|United Kingdom 1
United States|France|Germany|Spain 1
United States|France|Netherlands|United Kingdom 1
United States|France|Spain 1
United States|France|United Kingdom 1
United States|Germany 1
United States|Germany|Hong Kong|Japan 1
United States|Germany|Italy|Netherlands|Switzerland 1
United States|Germany|Italy|Spain|United Kingdom 1
United States|Germany|United Kingdom 1
United States|Israel|Korea, Republic of|Russian Federation 1
United States|Italy|United Kingdom 1
United States|Spain 1
United States|Switzerland 1
United States|Taiwan 1

Sites per Study

Site_count Study_Count
1 711
2 123
3 50
4 49
5 27
6 25
7 27
8 24
9 19
10 23
11 16
12 15
13 15
14 9
15 10
16 8
17 6
18 6
19 4
20 9
21 5
22 4
23 8
24 5
25 5
26 1
27 7
28 2
29 1
30 2
31 3
32 4
33 3
34 1
36 1
37 1
38 2
39 2
40 1
41 3
42 3
44 2
46 1
47 1
49 2
50 1
52 2
54 1
57 2
58 2
59 1
60 2
62 1
63 3
64 1
65 3
66 1
75 1
76 1
77 2
81 1
83 1
86 1
87 1
88 2
91 1
94 4
95 2
97 2
102 1
103 1
111 2
112 2
116 1
121 2
123 1
124 1
127 1
129 2
130 1
132 1
136 1
144 1
145 2
148 1
153 1
156 2
157 1
159 1
161 1
167 1
170 1
173 1
191 1
192 1
198 1
205 1
207 1
209 1
210 1
219 1
220 1
228 1
230 1
258 1
259 1
280 1
281 1
297 1
310 1
489 1
533 1
583 1
638 1
748 1
760 1
802 1
950 1
1329 1

Phase

Phase Study_Count
Phase 2 531
Phase 1 373
Phase 1/Phase 2 170
N/A 130
Phase 3 99
Early Phase 1 25
Phase 4 10
Phase 2/Phase 3 3

Number of Arms

Number_of_Arms Count_of_Studies
1 594
2 334
3 85
4 63
5 19
6 9
7 4
8 6
9 5
10 3
11 1
12 2
15 2
37 1
NA 213

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 1.00 1.0000 1.00000 1.0000 1.00000 9.0000 10.0000 6.0
1st Qu. 10.00 24.0000 16.00000 22.0000 25.00000 141.5000 249.5000 45.0
Median 20.00 84.0000 28.00000 41.0000 45.50000 274.0000 496.5000 87.0
Mean 22.28 319.0469 48.12079 71.7205 85.19008 327.6667 656.4479 130.1
3rd Qu. 27.00 353.5000 48.25000 90.0000 84.50000 487.0000 856.0000 150.0
Max. 108.00 4118.0000 1260.00000 557.0000 6452.00000 700.0000 3219.0000 413.0

Trial Group Type

group_type Group_Count
Experimental 1831
NA 213
Active Comparator 199
Other 63
No Intervention 38
Placebo Comparator 38
Sham Comparator 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 721
Parallel Assignment 424
NA 129
Sequential Assignment 40
Crossover Assignment 20
Factorial Assignment 7

Primary Purpose

primary_purpose Study_Count
Treatment 1184
Diagnostic 53
Prevention 43
Supportive Care 14
Other 13
NA 13
Basic Science 10
Screening 9
Health Services Research 2

Observational Studies

Studies by Country

Country Study_Count
United States 76
France 19
NA 14
Germany 9
United Kingdom 9
Canada 6
Netherlands 6
Denmark 3
Israel 3
Italy 3
Spain 3
Belgium 2
China 2
Ireland 2
Japan 2
Poland 2
Russian Federation 2
Switzerland 2
Australia 1
Austria 1
Austria|Belgium|Czechia|Germany|Ireland|Italy|Netherlands|Poland|Sweden|United Kingdom 1
Brazil 1
France|United States|Australia|Austria|Belgium|Germany|Italy|Puerto Rico|Spain|Switzerland|United Kingdom 1
Germany|Switzerland|Austria 1
Iceland 1
Italy|Spain 1
Sweden 1
Turkey 1
United States|Argentina|Australia|Austria|Belgium|Canada|France|Germany|Greece|Ireland|Israel|Poland|Spain|Switzerland|United Kingdom 1
United States|Australia 1
United States|Austria|Belgium|Czechia|Denmark|France|Germany|Hungary|Ireland|Italy|Netherlands|Norway|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Austria|Israel|Switzerland|United Kingdom 1
United States|Canada|Spain|Sweden|United Kingdom 1
United States|Finland|Iceland|Sweden 1
United States|United Kingdom 1
Venezuela 1

Sites per Study

Site_count Study_Count
1 135
2 9
3 6
4 2
5 4
6 2
7 1
8 1
9 1
11 3
12 1
13 3
17 2
22 2
24 1
27 1
29 1
31 1
33 2
35 1
66 1
80 1
88 1
176 1

Enrollment Metrics

Measure Observational
Min 1.00
1st Qu 58.00
Median 200.00
Mean 6517.47
3rd Qu 600.00
Max 1000000.00

Observation Model

observational_model Study_Count
Cohort 109
Case-Only 29
Other 13
Case-Control 10
NA 10
Case Control 6
Family-Based 4
Defined Population 1
Ecologic or Community 1

Time Perspective

time_perspective Study_Count
Prospective 112
Retrospective 39
Cross-Sectional 12
Other 10
NA 9
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
United States 5
NA 2
Belgium|France|Germany|Italy|Netherlands|Poland|Slovenia|Spain|Switzerland|United Kingdom 1
Canada 1
Spain 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 7
3 1
4 1
22 1
38 1

Enrollment Metrics

Measure Registries
Min 12.000
1st Qu 330.000
Median 500.000
Mean 1919.182
3rd Qu 2236.000
Max 9367.000

Registry Model

observational_model Study_Count
Cohort 6
Other 2
Case-Control 1
Ecologic or Community 1
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 10
Other 1

Follow-up

target_duration Study_Count
10 Years 6
5 Years 2
24 Months 1
3 Months 1
3 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT02393001 Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques https://ClinicalTrials.gov/show/NCT02393001 Completed University of Florida 2017-09-30
NCT03879395 Surgery for Gastrointestinal Metastases of Malignant Melanoma - a Single Center Retrospective Cohort Study https://ClinicalTrials.gov/show/NCT03879395 Completed Sahlgrenska University Hospital, Sweden 2018-12-31
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT03326973 Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT03326973 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT03199846 Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States https://ClinicalTrials.gov/show/NCT03199846 Completed Bristol-Myers Squibb 2017-10-30
NCT03197636 Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients https://ClinicalTrials.gov/show/NCT03197636 Enrolling by invitation Aarhus University Hospital 2020-07-01
NCT03165422 A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan https://ClinicalTrials.gov/show/NCT03165422 Completed Bristol-Myers Squibb 2018-12-29
NCT03165409 Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread https://ClinicalTrials.gov/show/NCT03165409 Completed Bristol-Myers Squibb 2017-09-30
NCT03155217 Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old https://ClinicalTrials.gov/show/NCT03155217 Completed University Hospital, Montpellier 2018-11-30
NCT03139513 A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) https://ClinicalTrials.gov/show/NCT03139513 Completed Hoffmann-La Roche 2018-08-22
NCT03050268 Familial Investigations of Childhood Cancer Predisposition https://ClinicalTrials.gov/show/NCT03050268 Recruiting St. Jude Children’s Research Hospital 2037-03-31
NCT02990611 Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy https://ClinicalTrials.gov/show/NCT02990611 Recruiting Bristol-Myers Squibb 2024-08-31
NCT02949154 Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients https://ClinicalTrials.gov/show/NCT02949154 Completed University Medical Center Groningen 2017-04-30
NCT02910557 Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection https://ClinicalTrials.gov/show/NCT02910557 Recruiting Amgen 2026-08-28
NCT02909348 Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab https://ClinicalTrials.gov/show/NCT02909348 Completed Royal Free Hospital NHS Foundation Trust 2019-10-31
NCT02907086 Circulating Tumor Material in Colorectal Cancer and Melanoma https://ClinicalTrials.gov/show/NCT02907086 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2020-08-31
NCT02884362 Prospective Melanoma Database https://ClinicalTrials.gov/show/NCT02884362 Recruiting Institut Claudius Regaud 2026-01-31
NCT02883933 Clinical and Histological Features of Head and Neck Melanoma https://ClinicalTrials.gov/show/NCT02883933 Completed CHU de Reims 2011-12-31
NCT02854488 Yervoy Pregnancy Surveillance Study https://ClinicalTrials.gov/show/NCT02854488 Recruiting Bristol-Myers Squibb 2024-08-31
NCT02854124 Tracing Dissemination of Melanoma Cells in Healthy Tissues https://ClinicalTrials.gov/show/NCT02854124 Recruiting Assistance Publique - Hôpitaux de Paris 2023-10-31
NCT02847728 Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice https://ClinicalTrials.gov/show/NCT02847728 Recruiting Bristol-Myers Squibb 2024-03-31
NCT02828202 Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients https://ClinicalTrials.gov/show/NCT02828202 Recruiting Assistance Publique - Hôpitaux de Paris 2021-03-31
NCT02794636 Interferon Toxicities in Melanoma Treatment https://ClinicalTrials.gov/show/NCT02794636 Completed Bristol-Myers Squibb 2015-11-30
NCT02780089 Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study https://ClinicalTrials.gov/show/NCT02780089 Active, not recruiting Bristol-Myers Squibb 2020-07-31
NCT02755233 Ipilimumab-induced Lung Toxicity: Observational Study https://ClinicalTrials.gov/show/NCT02755233 Completed University of Zurich 2015-12-31
NCT02739386 Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases https://ClinicalTrials.gov/show/NCT02739386 Completed Bristol-Myers Squibb 2017-03-30
NCT02724488 Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies https://ClinicalTrials.gov/show/NCT02724488 Active, not recruiting University Health Network, Toronto 2020-12-31
NCT02717364 Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma https://ClinicalTrials.gov/show/NCT02717364 Recruiting Bristol-Myers Squibb 2020-06-24
NCT02673970 Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma https://ClinicalTrials.gov/show/NCT02673970 Recruiting Universitair Ziekenhuis Brussel 2020-09-30
NCT02663232 Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma https://ClinicalTrials.gov/show/NCT02663232 Completed Hoffmann-La Roche 2014-10-31
NCT02668887 Employment and Quality of Life in Patients With Malignant Melanoma https://ClinicalTrials.gov/show/NCT02668887 Completed Fachklinik Hornheide an der Universität Münster 2018-08-31
NCT02600169 Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab https://ClinicalTrials.gov/show/NCT02600169 Completed University Medical Center Groningen 2019-04-30
NCT02600143 Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. https://ClinicalTrials.gov/show/NCT02600143 Completed University Medical Center Groningen 2019-04-30
NCT02791594 Imaging FDG Flare in Melanoma https://ClinicalTrials.gov/show/NCT02791594 Completed Abramson Cancer Center of the University of Pennsylvania 2020-07-01
NCT00040352 Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma https://ClinicalTrials.gov/show/NCT00040352 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02470273 Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID) https://ClinicalTrials.gov/show/NCT02470273 Active, not recruiting Rockefeller University 2021-07-31
NCT02439411 Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain https://ClinicalTrials.gov/show/NCT02439411 Completed Grupo Español Multidisciplinar de Melanoma 2016-09-30
NCT02425475 FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA) https://ClinicalTrials.gov/show/NCT02425475 Completed University Hospital Tuebingen 2016-07-31
NCT02372708 Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy https://ClinicalTrials.gov/show/NCT02372708 Completed Chinese PLA General Hospital 2012-05-31
NCT02352623 Quality of Life and Surgical Late Effects of Melanoma Treatment https://ClinicalTrials.gov/show/NCT02352623 Completed Herlev Hospital 2016-02-29
NCT02332642 Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy https://ClinicalTrials.gov/show/NCT02332642 Completed Universitätsmedizin Mannheim 2016-12-31
NCT02279004 A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care https://ClinicalTrials.gov/show/NCT02279004 Recruiting Dana-Farber Cancer Institute 2021-12-31
NCT02224768 YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey https://ClinicalTrials.gov/show/NCT02224768 Completed Bristol-Myers Squibb 2015-11-30
NCT02213471 Patient Preference for Biopsy Notification https://ClinicalTrials.gov/show/NCT02213471 Completed University of California, San Francisco 2013-07-31
NCT02193581 Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging https://ClinicalTrials.gov/show/NCT02193581 Completed Orlucent, Inc 2017-12-01
NCT02196246 Moletest Clinical Study in Scotland https://ClinicalTrials.gov/show/NCT02196246 Completed Moletest Scotland Ltd 2016-10-12
NCT02171286 The Oncopanel Pilot (TOP) Study https://ClinicalTrials.gov/show/NCT02171286 Completed British Columbia Cancer Agency 2017-03-31
NCT02177110 A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma https://ClinicalTrials.gov/show/NCT02177110 Active, not recruiting Cancer Trials Ireland 2020-08-31
NCT02143999 An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma https://ClinicalTrials.gov/show/NCT02143999 Completed Hoffmann-La Roche 2016-12-30
NCT02088762 Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm) https://ClinicalTrials.gov/show/NCT02088762 Completed University Hospital Inselspital, Berne 2012-12-31
NCT02074605 Cognitive Effects of Interferon in Patients With Melanoma https://ClinicalTrials.gov/show/NCT02074605 Completed University of Arizona 2010-05-31
NCT02058953 CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases https://ClinicalTrials.gov/show/NCT02058953 Completed University of Pittsburgh 2019-08-19
NCT01288963 IL-2 “SELECT” Tissue Collection Protocol in Patients With Advanced Melanoma https://ClinicalTrials.gov/show/NCT01288963 Active, not recruiting Dana-Farber Cancer Institute 2020-12-31
NCT02050594 Ipilimumab 12-month Intensive Pharmacovigilance Protocol https://ClinicalTrials.gov/show/NCT02050594 Completed Bristol-Myers Squibb 2015-02-28
NCT04045691 Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment https://ClinicalTrials.gov/show/NCT04045691 Recruiting Pierre Fabre Pharma GmbH 2026-12-31
NCT04217382 Pre Transplantation Melanoma https://ClinicalTrials.gov/show/NCT04217382 Recruiting Hospices Civils de Lyon 2022-02-27
NCT03356470 Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma https://ClinicalTrials.gov/show/NCT03356470 Enrolling by invitation University of Wisconsin, Madison 2021-03-31
NCT01773655 Clinical and Histopathologic Characteristics of BAP1 Mutations https://ClinicalTrials.gov/show/NCT01773655 Completed Memorial Sloan Kettering Cancer Center 2020-06-30
NCT00339222 Family Study of Melanoma in Italy https://ClinicalTrials.gov/show/NCT00339222 Completed National Institutes of Health Clinical Center (CC) 2020-06-30
NCT01986712 A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma https://ClinicalTrials.gov/show/NCT01986712 Active, not recruiting St. Luke’s Hospital and Health Network, Pennsylvania 2021-03-31
NCT01955941 Vascular Response to Brachytherapy Using Functional OCT https://ClinicalTrials.gov/show/NCT01955941 Active, not recruiting OHSU Knight Cancer Institute 2021-12-31
NCT01960634 Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma https://ClinicalTrials.gov/show/NCT01960634 Completed Grupo Español Multidisciplinar de Melanoma 2015-05-31
NCT01925599 BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma https://ClinicalTrials.gov/show/NCT01925599 Recruiting Greater Houston Retina Research 2022-01-31
NCT01920516 Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment https://ClinicalTrials.gov/show/NCT01920516 Recruiting International Group of Endovascular Oncology 2019-06-30
NCT01924923 New Biopsy Technique for Uveal Melanoma https://ClinicalTrials.gov/show/NCT01924923 Completed Greater Houston Retina Research 2015-03-31
NCT01840527 Utility of Novel BRAF Test for Melanoma https://ClinicalTrials.gov/show/NCT01840527 Active, not recruiting Massachusetts General Hospital 2017-03-29
NCT01777802 Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy https://ClinicalTrials.gov/show/NCT01777802 Recruiting Mayo Clinic 2020-12-31
NCT01775514 A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics https://ClinicalTrials.gov/show/NCT01775514 Completed Hoffmann-La Roche 2015-10-31
NCT01776905 In Vivo Real-time Detection of Circulating Melanoma Cells https://ClinicalTrials.gov/show/NCT01776905 Recruiting University of Arkansas 2020-08-31
NCT03535077 Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) https://ClinicalTrials.gov/show/NCT03535077 Recruiting Orlucent, Inc 2020-05-31
NCT01744860 Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples https://ClinicalTrials.gov/show/NCT01744860 Completed Hoffmann-La Roche 2013-04-30
NCT01703585 Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples https://ClinicalTrials.gov/show/NCT01703585 Completed University Health Network, Toronto 2018-05-01
NCT03438279 Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy https://ClinicalTrials.gov/show/NCT03438279 Completed Bristol-Myers Squibb 2017-12-28
NCT01558349 Circulating Tumor Cells and Melanoma: Comparing the EPISPOT and CellSearch Techniques https://ClinicalTrials.gov/show/NCT01558349 Completed Centre Hospitalier Universitaire de Nīmes 2017-06-27
NCT01556503 Sensitivity/Specificity Study of Non-invasive Imaging for Melanoma Diagnosis https://ClinicalTrials.gov/show/NCT01556503 Completed OHSU Knight Cancer Institute 2013-11-30
NCT01531608 Evaluation Of Mobile Gamma Camera Imaging For Sentinel Node Biopsy In Melanoma https://ClinicalTrials.gov/show/NCT01531608 Completed University of Virginia 2012-02-29
NCT01528774 Culture and Characterization of Circulating Tumor Cells (CTC) in Melanoma and Other Cancers https://ClinicalTrials.gov/show/NCT01528774 Completed Comprehensive Cancer Centers of Nevada 2016-06-30
NCT01511913 A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma https://ClinicalTrials.gov/show/NCT01511913 Active, not recruiting Bristol-Myers Squibb 2020-05-11
NCT01482260 Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma https://ClinicalTrials.gov/show/NCT01482260 Completed Ruhr University of Bochum 2012-01-31
NCT01444560 miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi https://ClinicalTrials.gov/show/NCT01444560 Completed Ruhr University of Bochum 2011-09-30
NCT01438658 Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma https://ClinicalTrials.gov/show/NCT01438658 Recruiting Hadassah Medical Organization 2040-12-31
NCT01433302 Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass https://ClinicalTrials.gov/show/NCT01433302 Completed M.D. Anderson Cancer Center 2014-03-31
NCT01388569 Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim https://ClinicalTrials.gov/show/NCT01388569 Completed Eastern Cooperative Oncology Group 2011-09-28
NCT01387581 Does the Aid of MelaFind Affect Clinical Management Decisions https://ClinicalTrials.gov/show/NCT01387581 Completed MELA Sciences, Inc. 2012-03-31
NCT01336270 Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients https://ClinicalTrials.gov/show/NCT01336270 Completed Assistance Publique - Hôpitaux de Paris 2013-11-30
NCT04334824 Hydrochlorothiazide and Risk of Skin Cancer https://ClinicalTrials.gov/show/NCT04334824 Active, not recruiting Canadian Network for Observational Drug Effect Studies, CNODES 2021-06-30
NCT04272658 PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy https://ClinicalTrials.gov/show/NCT04272658 Recruiting University Hospital, Brest 2023-01-31
NCT04253574 Comparison of PET/CT and Ultrasound in Staging of Malignant Melanoma https://ClinicalTrials.gov/show/NCT04253574 Completed University of Basel 2017-09-01
NCT04196452 A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) https://ClinicalTrials.gov/show/NCT04196452 Active, not recruiting Bristol-Myers Squibb 2029-03-31
NCT04193956 POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT04193956 Recruiting University Medical Center Groningen 2023-07-31
NCT04169867 Polish Microbiome Map https://ClinicalTrials.gov/show/NCT04169867 Recruiting Ardigen 2020-07-31
NCT04158544 Immune Monitoring in Metastatic Melanoma https://ClinicalTrials.gov/show/NCT04158544 Recruiting University of Regensburg 2020-07-31
NCT04154163 Appropriate Dosing to Optimise Personalised Cancer Treatments https://ClinicalTrials.gov/show/NCT04154163 Recruiting University of Dundee 2020-07-30
NCT04146324 An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia https://ClinicalTrials.gov/show/NCT04146324 Recruiting Bristol-Myers Squibb 2025-07-09
NCT04136470 BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics https://ClinicalTrials.gov/show/NCT04136470 Recruiting Ardigen 2020-09-30
NCT04095195 Registry of Subjects at Risk of Pancreatic Cancer https://ClinicalTrials.gov/show/NCT04095195 Recruiting Associazione Italiana per lo Studio del Pancreas 2044-08-20
NCT04067960 Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer https://ClinicalTrials.gov/show/NCT04067960 Recruiting Mayo Clinic 2020-12-31
NCT04056247 Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments https://ClinicalTrials.gov/show/NCT04056247 Recruiting OncoHost Ltd. 2021-10-01
NCT04025424 Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519) https://ClinicalTrials.gov/show/NCT04025424 Recruiting Russian Academy of Medical Sciences 2021-06-30
NCT03964298 Study of the Activity of PD-1 Inhibitors in Metastatic Uveal Melanoma https://ClinicalTrials.gov/show/NCT03964298 Enrolling by invitation Institut Curie 2019-11-30
NCT03946007 Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT03946007 Recruiting University Medical Center Groningen 2021-06-30
NCT03843593 A Study To See Why Patients Agree To or Decline To Have Treatment After Surgery https://ClinicalTrials.gov/show/NCT03843593 Recruiting Memorial Sloan Kettering Cancer Center 2021-02-28
NCT03798977 Preclinical Validation of New Anti-melanoma Compounds https://ClinicalTrials.gov/show/NCT03798977 Recruiting Centre Hospitalier Universitaire de Nice 2019-12-31
NCT03771859 A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed https://ClinicalTrials.gov/show/NCT03771859 Recruiting Bristol-Myers Squibb 2025-12-07
NCT03740503 Genomic Investigation of Unusual Responders https://ClinicalTrials.gov/show/NCT03740503 Active, not recruiting University Health Network, Toronto 2020-11-30
NCT03741231 18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy https://ClinicalTrials.gov/show/NCT03741231 Completed University Hospital, Brest 2018-06-30
NCT03728842 Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03728842 Recruiting Indiana University 2021-03-01
NCT03732560 A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US https://ClinicalTrials.gov/show/NCT03732560 Active, not recruiting Bristol-Myers Squibb 2019-04-30
NCT03696069 A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma https://ClinicalTrials.gov/show/NCT03696069 Active, not recruiting Bristol-Myers Squibb 2019-02-22
NCT03693378 A Study of IMMrayâ„¢ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups https://ClinicalTrials.gov/show/NCT03693378 Recruiting Immunovia, Inc. 2020-10-31
NCT03663647 Advanced Melanoma in Russian Experience https://ClinicalTrials.gov/show/NCT03663647 Recruiting MelanomaPRO, Russia 2019-01-31
NCT03553329 Study of the Variations of Albumin Level for Patients With Unresecable Stage IIIc or Stage IV Melanoma Treated by Anti BRAF and Anti MEK https://ClinicalTrials.gov/show/NCT03553329 Completed Poitiers University Hospital 2018-06-02
NCT03518814 Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM) https://ClinicalTrials.gov/show/NCT03518814 Completed Lille Catholic University 2018-06-05
NCT03508297 Reflectance Confocal Microscopy to Diagnose MM & LM https://ClinicalTrials.gov/show/NCT03508297 Recruiting Skin Care Network Ltd. 2019-12-31
NCT03450876 Long Term Quality of Life in Melanoma Patients in Netherlands https://ClinicalTrials.gov/show/NCT03450876 Recruiting Bristol-Myers Squibb 2020-05-29
NCT03448497 Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom https://ClinicalTrials.gov/show/NCT03448497 Completed Bristol-Myers Squibb 2018-04-27
NCT01253759 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma https://ClinicalTrials.gov/show/NCT01253759 Completed New England Retina Associates 2009-01-31
NCT01209299 Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate https://ClinicalTrials.gov/show/NCT01209299 Completed Eastern Cooperative Oncology Group 2012-02-19
NCT01205815 Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment https://ClinicalTrials.gov/show/NCT01205815 Recruiting Vanderbilt-Ingram Cancer Center 2020-12-31
NCT01118832 Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi https://ClinicalTrials.gov/show/NCT01118832 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2010-06-29
NCT01034696 Pain Prevalence and Risk Factors Among Sarcoma/Melanoma Oncology Patients in an Outpatients Setting https://ClinicalTrials.gov/show/NCT01034696 Completed Royal Marsden NHS Foundation Trust 2010-01-31
NCT01011153 Survey Study - Sensitivity Comparison Between MelaFind and Physician Group https://ClinicalTrials.gov/show/NCT01011153 Completed MELA Sciences, Inc. 2010-02-28
NCT01004952 Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection https://ClinicalTrials.gov/show/NCT01004952 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-10-31
NCT00974610 Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, Pancreatic Cancer, or Colorectal Cancer. https://ClinicalTrials.gov/show/NCT00974610 Completed Cancer Trials Ireland 2015-12-31
NCT00952939 Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye https://ClinicalTrials.gov/show/NCT00952939 Completed Case Comprehensive Cancer Center 2012-09-30
NCT00937781 Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690 https://ClinicalTrials.gov/show/NCT00937781 Completed Eastern Cooperative Oncology Group 2011-08-08
NCT00937690 Pilot Study of Infrared Imaging of Cutaneous Melanoma https://ClinicalTrials.gov/show/NCT00937690 Completed University of Virginia 2009-09-30
NCT00928031 Long-term Data Collection for Subjects in MDX-010 Studies https://ClinicalTrials.gov/show/NCT00928031 Completed Bristol-Myers Squibb 2009-04-30
NCT00923026 Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies https://ClinicalTrials.gov/show/NCT00923026 Enrolling by invitation National Institutes of Health Clinical Center (CC) NA
NCT00901966 Sun Exposure and Melanoma in Agricultural Workers https://ClinicalTrials.gov/show/NCT00901966 Completed National Institutes of Health Clinical Center (CC) NA
NCT00897624 Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma https://ClinicalTrials.gov/show/NCT00897624 Completed National Cancer Institute (NCI) 2011-05-31
NCT00898183 S9431: Studying Genes and Immune Response in Tumor Samples From Patients With Locally Advanced or Metastatic Melanoma https://ClinicalTrials.gov/show/NCT00898183 Completed Southwest Oncology Group 2006-02-28
NCT00897546 Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma https://ClinicalTrials.gov/show/NCT00897546 Completed Eastern Cooperative Oncology Group 2008-07-01
NCT00897520 Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy https://ClinicalTrials.gov/show/NCT00897520 Completed Eastern Cooperative Oncology Group 2010-01-24
NCT00889980 Melanoma Molecular Profiling Analysis https://ClinicalTrials.gov/show/NCT00889980 Completed University of Pittsburgh 2019-07-22
NCT00862914 Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi https://ClinicalTrials.gov/show/NCT00862914 Completed Ruhr University of Bochum 2009-02-28
NCT00912730 A Pilot Study of Intraoperative Gamma Camera Imaging During Sentinel Node Biopsy for Melanoma https://ClinicalTrials.gov/show/NCT00912730 Completed University of Virginia NA
NCT00849407 Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma https://ClinicalTrials.gov/show/NCT00849407 Recruiting Medical University of Vienna 2020-12-31
NCT00839410 Multicentric Cohort of Melanoma Patients in Ile de France Area https://ClinicalTrials.gov/show/NCT00839410 Completed Assistance Publique - Hôpitaux de Paris 2019-10-31
NCT03643289 Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics https://ClinicalTrials.gov/show/NCT03643289 Recruiting East and North Hertfordshire NHS Trust 2023-05-02
NCT00832533 The Response of Serum 25-Hydroxyvitamin D to Incidental Ultraviolet Light Exposure https://ClinicalTrials.gov/show/NCT00832533 Completed New Mexico Cancer Care Alliance 2009-02-28
NCT00828126 PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma https://ClinicalTrials.gov/show/NCT00828126 Completed M.D. Anderson Cancer Center 2012-03-31
NCT03944356 BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients https://ClinicalTrials.gov/show/NCT03944356 Recruiting EuMelaReg gGmbH 2021-06-30
NCT03941379 A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs) https://ClinicalTrials.gov/show/NCT03941379 Recruiting Aura Biosciences 2029-12-31
NCT03504696 Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma https://ClinicalTrials.gov/show/NCT03504696 Completed Bristol-Myers Squibb 2018-02-20
NCT03319693 Molecular Characterization of Primary Mucosal Melanoma https://ClinicalTrials.gov/show/NCT03319693 Active, not recruiting CHU de Reims 2019-04-28
NCT01990248 An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS) https://ClinicalTrials.gov/show/NCT01990248 Completed Hoffmann-La Roche 2016-07-26
NCT01505400 Integrated Molecular Profiling in Advanced Cancers Trial https://ClinicalTrials.gov/show/NCT01505400 Active, not recruiting University Health Network, Toronto 2021-01-31
NCT00341991 Molecular Epidemiology of Cutaneous Malignant Melanoma https://ClinicalTrials.gov/show/NCT00341991 Completed National Institutes of Health Clinical Center (CC) 2007-09-26
NCT00026754 Eligibility Screening and Tissue Procurement for the NIH Intramural Research Program Clinical Protocols https://ClinicalTrials.gov/show/NCT00026754 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02784366 GI Complications in Cancer Immunotherapy Patients https://ClinicalTrials.gov/show/NCT02784366 Recruiting Massachusetts General Hospital 2020-03-31
NCT02378337 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality https://ClinicalTrials.gov/show/NCT02378337 Completed Hospital Sao Rafael 2015-08-31
NCT02492815 PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma https://ClinicalTrials.gov/show/NCT02492815 Completed Bristol-Myers Squibb 2016-04-30
NCT01489423 Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim https://ClinicalTrials.gov/show/NCT01489423 Completed Eastern Cooperative Oncology Group 2013-05-26
NCT03966456 Real World Study of Four PD-1 Agents in China https://ClinicalTrials.gov/show/NCT03966456 Recruiting The Affiliated Hospital of Qingdao University 2021-06-01
NCT00749684 Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) https://ClinicalTrials.gov/show/NCT00749684 Completed Merck Sharp & Dohme Corp. 2009-09-30
NCT00745862 Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma https://ClinicalTrials.gov/show/NCT00745862 Completed Memorial Sloan Kettering Cancer Center 2013-07-31
NCT00723710 Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) https://ClinicalTrials.gov/show/NCT00723710 Completed Merck Sharp & Dohme Corp. 2012-09-30
NCT00617799 Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma https://ClinicalTrials.gov/show/NCT00617799 Completed University of Nebraska 2009-02-18
NCT00615095 Differential Risks for Melanoma: p16 and DNA Repair https://ClinicalTrials.gov/show/NCT00615095 Completed Memorial Sloan Kettering Cancer Center 2011-04-30
NCT00597961 Health Communication in Families https://ClinicalTrials.gov/show/NCT00597961 Completed Memorial Sloan Kettering Cancer Center 2020-04-14
NCT00591500 A Model for Genetic Susceptibility: Melanoma https://ClinicalTrials.gov/show/NCT00591500 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-07-31
NCT00581698 Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue https://ClinicalTrials.gov/show/NCT00581698 Completed Memorial Sloan Kettering Cancer Center 2009-09-30
NCT00588198 Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma https://ClinicalTrials.gov/show/NCT00588198 Completed Memorial Sloan Kettering Cancer Center 2009-09-30
NCT00540566 Optical Biopsy of Human Skin in Conjunction With Laser Treatment https://ClinicalTrials.gov/show/NCT00540566 Completed University of California, Irvine 2008-06-30
NCT00536029 MicroRNA Expression and Function in Cutaneous Malignant Melanoma https://ClinicalTrials.gov/show/NCT00536029 Completed Rigshospitalet, Denmark NA
NCT00526032 Melanoma Detection by Oblique-Incidence Optical Spectroscopy https://ClinicalTrials.gov/show/NCT00526032 Completed M.D. Anderson Cancer Center 2012-01-31
NCT00518050 Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns https://ClinicalTrials.gov/show/NCT00518050 Completed Memorial Sloan Kettering Cancer Center 2015-07-31
NCT00510302 Melanoma Risk-Reduction Among Patients and Family Members https://ClinicalTrials.gov/show/NCT00510302 Active, not recruiting M.D. Anderson Cancer Center 2020-11-30
NCT00507325 Sample Collection From Melanoma Patients https://ClinicalTrials.gov/show/NCT00507325 Active, not recruiting M.D. Anderson Cancer Center 2020-06-30
NCT00495950 Prospective Measurement of Post-Treatment Lymphedema https://ClinicalTrials.gov/show/NCT00495950 Completed M.D. Anderson Cancer Center 2016-11-30
NCT00450593 Identifying Gene Mutations in Patients With Melanoma and in Families With a History of Hereditary Melanoma https://ClinicalTrials.gov/show/NCT00450593 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT00445783 Study of Families With Melanoma https://ClinicalTrials.gov/show/NCT00445783 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT00368615 Characterization of the Melanoma-Specific Immune Response https://ClinicalTrials.gov/show/NCT00368615 Recruiting University of California, Davis 2021-04-30
NCT00351728 Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone https://ClinicalTrials.gov/show/NCT00351728 Completed Jonsson Comprehensive Cancer Center 2012-08-31
NCT00348088 Melanoma Biomarker Study https://ClinicalTrials.gov/show/NCT00348088 Completed Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2011-09-30
NCT00346008 Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members https://ClinicalTrials.gov/show/NCT00346008 Completed National Cancer Institute (NCI) 2008-12-31
NCT00339404 Genetic Analysis of Familial Melanoma https://ClinicalTrials.gov/show/NCT00339404 Completed National Institutes of Health Clinical Center (CC) NA
NCT00344799 Cytogenetic Study of Ocular Melanoma https://ClinicalTrials.gov/show/NCT00344799 Recruiting Jonsson Comprehensive Cancer Center 2020-12-31
NCT00288938 Natural History Study of Moles and Suspicious Melanoma https://ClinicalTrials.gov/show/NCT00288938 Completed National Institutes of Health Clinical Center (CC) NA
NCT00203008 A Survey Study to See if Patients Diagnosed With Parkinson’s Disease Have Higher Incidence of Melanoma https://ClinicalTrials.gov/show/NCT00203008 Completed Teva Pharmaceutical Industries NA
NCT00132704 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation https://ClinicalTrials.gov/show/NCT00132704 Completed Memorial Sloan Kettering Cancer Center 2014-07-31
NCT00001898 Microarray Analysis for Human Genetic Disease https://ClinicalTrials.gov/show/NCT00001898 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02376920 5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes https://ClinicalTrials.gov/show/NCT02376920 Active, not recruiting Castle Biosciences Incorporated 2020-10-31
NCT03379454 The Impact of Melanoma and Drug Treatment in the Real World https://ClinicalTrials.gov/show/NCT03379454 Recruiting Vitaccess Ltd 2022-10-25
NCT02775643 Molecular Analysis of Childhood and Adolescent Melanocytic Lesions https://ClinicalTrials.gov/show/NCT02775643 Active, not recruiting St. Jude Children’s Research Hospital 2031-05-31
NCT02355587 Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes https://ClinicalTrials.gov/show/NCT02355587 Active, not recruiting Castle Biosciences Incorporated 2024-02-29
NCT02355574 5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results https://ClinicalTrials.gov/show/NCT02355574 Active, not recruiting Castle Biosciences Incorporated 2024-02-29
NCT02251314 Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma https://ClinicalTrials.gov/show/NCT02251314 Completed University Health Network, Toronto 2015-01-31
NCT02206360 Pancreatic Cancer Early Detection Program https://ClinicalTrials.gov/show/NCT02206360 Recruiting White Plains Hospital 2024-03-31
NCT01942603 Minimal SN Tumor Burden https://ClinicalTrials.gov/show/NCT01942603 Recruiting European Organisation for Research and Treatment of Cancer - EORTC 2023-07-31
NCT03605771 Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain https://ClinicalTrials.gov/show/NCT03605771 Recruiting Grupo Español Multidisciplinar de Melanoma 2020-09-30
NCT03174574 Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer. https://ClinicalTrials.gov/show/NCT03174574 Recruiting Mayo Clinic 2021-06-30
NCT03169036 Melanomas Excised in Primary Care vs Secondary Care Excision https://ClinicalTrials.gov/show/NCT03169036 Completed University of Aberdeen 2017-05-01